Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025
December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2 Against that backdrop, investors are trying to decide whether TEVA is simply “priced for the pivot” or